Pain Market Research Reports & Industry Analysis
In considering the IASP definition, it is important to note that not all potentially tissue-damaging stimuli result in pain. Nociception is the activation of the primary afferent nerves with peripheral terminals that respond differently to noxious stimuli. Nociceptors function primarily to sense and transmit pain signals. Nociception may or may not be perceived as pain, depending on a complex interaction within the nociceptive pathways. If nociceptive stimuli are blocked, pain is not perceived. Finally, it is important to distinguish pain, or nociception, from suffering. Suffering is the state of severe distress associated with events that threaten the intactness of the person. Suffering is an emotion. Pain and suffering are not the same phenomenon.
The person who complained of pain in the heart because of the death of a loved one is suffering rather than experiencing pain as it is defined by the IASP. It is clear that three conditions could exist: 1) suffering occurs in the presence of pain,2) suffering occurs when pain is not present, and 3) pain occurs when suffering is not present. For example, the woman awaiting breast biopsy may suffer because of anticipated loss of her breast. After the biopsy, she may have pain without suffering if the biopsy is negative or pain with suffering if the biopsy is positive for malignancy. Interventions aimed at relieving pain and suffering may have some commonalities, but clearly some interventions for suffering will be inadequate for pain just as some interventions for pain are inadequate for suffering.
Pain Industry Research & Market Reports
-
The 2026-2031 World Outlook for Companion Animal Postoperative Pain Management Therapeutics
... the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. ... Read More
-
The 2026-2031 World Outlook for Anesthetic Pain Management
... question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric models ... Read More
-
The 2026-2031 World Outlook for Critical Limb Ischemia Treatments
... in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric ... Read More
-
The 2026-2031 World Outlook for Antiepileptic Therapeutics for Fibromyalgia
... in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric ... Read More
-
The 2026-2031 World Outlook for Cancer Pain Management
... question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric models ... Read More
-
The 2026-2031 World Outlook for Analgesics
... millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric models which project ... Read More
-
The 2026-2031 World Outlook for Geriatric Analgesic Medicines
... question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric models ... Read More
-
The 2026-2031 World Outlook for Cold Pain Therapies
... question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric models ... Read More
-
The 2026-2031 World Outlook for Analgesics (Painkillers)
... (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric models which ... Read More
-
The 2026-2031 World Outlook for Cancer Pain
... (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric models which ... Read More
-
The 2026-2031 World Outlook for Anti-Migraine Drugs
... (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric models which ... Read More
-
The 2026-2031 World Outlook for Acute-Treatment Migraine Drugs
... question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric models ... Read More
-
The 2026-2031 World Outlook for Fibromyalgia Therapeutics
... (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric models which ... Read More
-
Chronic Pain Market, By Drug Class (Opioids, Non-steroidal anti-inflammatory drugs (NSAIDS), Anticonvulsants, Antidepressants, and Others), By Indication (Neuropathic pain, Arthritis pain, Chronic back pain, Cancer pain, Migraine, Fibromyalgia, and Others), By Application (Musculoskeletal, Neuropathy, Oncology, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)
... neurological disorders and fibromyalgia among others. Sedentary lifestyles and rising chronic diseases can increase the prevalence of chronic pain globally. It negatively impacts quality of life by limiting mobility and daily functioning. Global chronic pain ... Read More
-
Global Chronic Lower Back Pain Drugs Market - 2025-2033
... a CAGR of 6.4% during the forecast period of 2025-2033. Lower back pain that is long-term (for more than 3 months) is called chronic lower back pain. This condition might originate from an injury, disease, ... Read More
-
Bovine Mastitis Market, by Type (Clinical Mastitis and Sub-clinical Mastitis), by Product (Antibiotics, Vaccines, Pain Killers, and Others), by Route of Administration (Intra-mammary and Systemic), by Therapy (Lactating Period, Dry Period (Antibiotics, and Teat Sealants)), by End User (Veterinary Centers, Hospital, Clinics, and Others), and by Region (North America, Europe, Asia Pacific, Middle East, Africa, and Latin America) - Size, Share, Outlook, and Opportunity Analysis, 2025 - 2032
... prevalent in dairy cows globally. It's a condition known for causing damage on the dairy industry's profit margin. Mastitis is caused by a huge number of different microorganism species. Viruses, mycoplasmas, fungi, and bacteria are ... Read More
-
Thailand Medical Cannabis Market Report by Cultivated Species (Indica, Sativa, Hybrid), Derivatives (Cannabidiol (CBD), Tetrahydrocannabinol (THC), and Others), Application Areas (Cancer, Arthritis, Migraine, Epilepsy, and Others), End-Use (Pharmaceuticals, Research and Development Centres, and Others), Route of Administration (Oral Solutions and Capsules, Vaporizers, Topicals, and Others) 2025-2033
... The market is propelled by the favorable government regulatory framework, widespread acceptance of the product, rapid growth of cultivation facilities and production capacity, increasing research and development (R&D) activities by key players, rising international investments ... Read More
-
Companion Animal Postoperative Pain Management Therapeutics
... reach US$306.2 Million by 2030, growing at a CAGR of 8.6% over the analysis period 2024-2030. NSAIDs, one of the segments analyzed in the report, is expected to record a 9.6% CAGR and reach US$178.7 ... Read More
-
Cancer Supportive Care
... at a CAGR of 2.2% over the analysis period 2024-2030. Opioids, one of the segments analyzed in the report, is expected to record a 2.3% CAGR and reach US$11.1 Billion by the end of the ... Read More
-
Over-the-Counter Pain Medication
... at a CAGR of 2.7% over the analysis period 2024-2030. Non-steroidal Anti-inflammatory Drugs, one of the segments analyzed in the report, is expected to record a 2.1% CAGR and reach US$12.1 Billion by the end ... Read More
-
Migraine Drugs
... CAGR of 16.0% over the analysis period 2024-2030. Acute Treatment, one of the segments analyzed in the report, is expected to record a 16.6% CAGR and reach US$7.2 Billion by the end of the analysis ... Read More
-
Nanocapsules
... 6.3% over the analysis period 2024-2030. Oncology, one of the segments analyzed in the report, is expected to record a 7.1% CAGR and reach US$2.0 Billion by the end of the analysis period. Growth in ... Read More
-
Radiofrequency Ablation Devices for Pain Management
... reach US$1.4 Billion by 2030, growing at a CAGR of 9.9% over the analysis period 2024-2030. Disposable Products, one of the segments analyzed in the report, is expected to record a 9.9% CAGR and reach ... Read More
-
Intrathecal Pumps
... CAGR of 5.1% over the analysis period 2024-2030. Morphine, one of the segments analyzed in the report, is expected to record a 4.9% CAGR and reach US$115.9 Million by the end of the analysis period. ... Read More
-
Cancer Pain Management
... at a CAGR of 3.6% over the analysis period 2024-2030. Acute Pain Type, one of the segments analyzed in the report, is expected to record a 2.8% CAGR and reach US$4.1 Billion by the end ... Read More
Research Assistance
